Q32 Bio Announces $55 Million Private Placement Financing

Rhea-AI Summary

Q32 Bio (NASDAQ:QTTB) entered a securities purchase agreement for a private placement of common stock and pre-funded warrants totaling approximately $55 million. The company will issue 6,725,000 shares at $8.00 and pre-funded warrants for 150,000 shares at $7.9999, led by BVF Partners, with closing expected May 28, 2026.

AI-generated analysis. Not financial advice.

Positive

• Approximately $55 million in gross proceeds expected from the private placement
• Issuance of 6,725,000 common shares at a defined price of $8.00 per share
• Additional 150,000 pre-funded warrants immediately exercisable at a $0.0001 exercise price
• Participation from institutional investors including BVF Partners, RA Capital, OrbiMed, Atlas Venture
• Q32 Bio plans to file an SEC registration statement for resale of shares and warrant shares

Negative

• Common stock and pre-funded warrants together cover 6,875,000 shares of Q32 Bio common stock
• Net proceeds will be lower than $55 million after placement agent fees and expenses
• Securities are initially unregistered under the Securities Act, limiting immediate public resale

News Market Reaction – QTTB

+81.24% 72.3x vol

47 alerts

+81.24% News Effect

+91.5% Peak Tracked

-15.1% Trough Tracked

+$99M Valuation Impact

$221.96M Market Cap

72.3x Rel. Volume

On the day this news was published, QTTB gained 81.24%, reflecting a significant positive market reaction. Argus tracked a peak move of +91.5% during that session. Argus tracked a trough of -15.1% from its starting point during tracking. Our momentum scanner triggered 47 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $99M to the company's valuation, bringing the market cap to $221.96M at that time. Trading volume was exceptionally heavy at 72.3x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Private placement size: $55 million Shares issued: 6,725,000 shares Offering price: $8.00 per share +5 more

8 metrics

Private placement size $55 million Aggregate gross proceeds from May 2026 private placement

Shares issued 6,725,000 shares Common stock sold at $8.00 in private placement

Offering price $8.00 per share Price of common stock in private placement

Pre-funded warrants 150,000 warrants Pre-funded warrants to purchase common stock in placement

Warrant price $7.9999 per warrant Price per pre-funded warrant, equal to $8.00 less $0.0001 exercise

Warrant exercise price $0.0001 Exercise price per share for pre-funded warrants

Quarterly net loss $7.6 million Net loss for quarter ended March 31, 2026 (10-Q)

Cash balance $50.8 million Cash and cash equivalents as of March 31, 2026 (10-Q)

Market Reality Check

Price: $11.05 Vol: Volume 293,837 is 14% abo...

normal vol

$11.05 Last Close

Volume Volume 293,837 is 14% above the 20-day average of 258,853, indicating elevated trading ahead of the financing news. normal

Technical Shares at $7.09 are trading above the 200-day MA of $3.79 and within 12% of the 52-week high of $8.045.

Peers on Argus

QTTB is up 22.24% while momentum peers are mixed: NNVC up 17.79% and AKTX down 4...

1 Up 1 Down

QTTB is up 22.24% while momentum peers are mixed: NNVC up 17.79% and AKTX down 4.55%. Broader biotech peers like LIXT, SABS, CRIS, and XCUR also show varied moves, pointing to a stock-specific reaction to QTTB’s financing.

Historical Context

5 past events · Latest: May 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 05	Q1 2026 earnings	Positive	+2.0%	Reported Q1 2026 results, cash of $50.8M, and runway into 1H 2028.
Apr 08	Conference participation	Neutral	-7.3%	Announced participation in the 25th Annual Needham Virtual Healthcare Conference.
Mar 10	Q4 2025 earnings	Positive	+17.4%	Q4 2025 results, completed SIGNAL-AA Part B enrollment and ADX-097 asset sale.
Feb 18	Conference appearance	Neutral	-5.4%	Disclosed fireside chat at Oppenheimer 36th Annual Healthcare Life Sciences Conference.
Feb 17	Registered direct offering	Negative	+9.7%	$10.5M registered direct equity financing to fund working capital and trials.

Pattern Detected

Recent financings and earnings updates have often coincided with positive price reactions, while conference participation has seen weaker or negative moves. The February $10.5M registered direct offering and Q4 2025 earnings both aligned with notable gains, suggesting investors have previously rewarded capital-raising tied to pipeline progress.

Recent Company History

Over the past few months, Q32 Bio has combined clinical and financing milestones. In February 2026, it announced a $10.5M registered direct offering and later reported Q4 2025 and Q1 2026 results highlighting cash of $50.8M and runway into 1H 2028. Conference appearances in February and April drew mixed to negative price reactions. Against this backdrop, the new $55M private placement extends a pattern of equity financings supporting development of bempikibart and alopecia areata programs.

Market Pulse Summary

The stock surged +81.2% in the session following this news. A strong positive reaction aligns with Q...

Analysis

The stock surged +81.2% in the session following this news. A strong positive reaction aligns with Q32 Bio’s recent pattern of financing-linked gains, as seen after the February $10.5M registered direct offering. The new $55M private placement adds to a cash position of $50.8M as of March 31, 2026, supporting development of alopecia areata programs. However, the issuance of 6,725,000 shares and 150,000 pre-funded warrants increases dilution, which could pressure the stock if sentiment toward equity raises shifts.

Key Terms

private placement, securities purchase agreement, pre-funded warrants, accredited investors, +2 more

6 terms

private placement financial

"for the private placement of common stock and pre-funded warrants for an aggregate"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

securities purchase agreement financial

"announced that it has entered into a securities purchase agreement with certain new"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

pre-funded warrants financial

"and (ii) pre-funded warrants to purchase 150,000 shares of Common Stock, at a price"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

accredited investors financial

"with certain new and existing institutional and accredited investors for the private"

Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.

placement agent financial

"Morgan Stanley acted as lead placement agent and Oppenheimer & Co. acted as a placement"

A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.

registration statement regulatory

"Q32 Bio has agreed to file a registration statement with the Securities and Exchange"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., May 27, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors for the private placement of common stock and pre-funded warrants for an aggregate of approximately $55 million.

In this private placement, the Company has agreed to issue and sell to such institutional and accredited investors (i) 6,725,000 shares (the "Shares") of the Company's common stock, $0.0001 par value per share (the "Common Stock"), at a price of $8.00 per share, and (ii) pre-funded warrants to purchase 150,000 shares of Common Stock, at a price of $7.9999 per pre-funded warrant, which equals the per share price of $8.00 less the exercise price $0.0001 for such pre-funded warrant. The pre-funded warrants are immediately exercisable and will expire when exercised in full. Q32 Bio anticipates the gross proceeds from the private placement to be approximately $55 million, before deducting fees to the placement agents and other offering expenses payable by the Company. The private placement is expected to close on May 28, 2026, subject to customary closing conditions.

The private placement is being led by BVF Partners L.P., with participation from RA Capital Management, OrbiMed, and Atlas Venture.

Morgan Stanley acted as lead placement agent and Oppenheimer & Co. acted as a placement agent in the private placement.

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended ("Securities Act"), or any state or other applicable jurisdiction's securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. Q32 Bio has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the Shares and the shares of Common Stock issuable upon the exercise of the pre-funded warrants issued in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or other jurisdiction.

About Q32 Bio

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata¹, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

¹National Alopecia Areata Foundation

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, ‎‎"forward-looking information") within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the ‎use of forward-looking terminology such as "plans", "excited to", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", ‎‎"is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and ‎phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be ‎achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or ‎circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the expected timing for the closing of the private placement and the potential exercise of the pre-funded warrants. Statements containing forward-looking information are not historical facts but instead represent management's current ‎expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events ‎and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to ‎known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, ‎performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the Company's ability to satisfy the closing conditions for the private placement, Company's ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the "Risk Factors" section of the Company's most recently Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission, and subsequent quarterly reports. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts:
Investors: Brendan Burns
Argot Partners
212.600.1902
Q32Bio@argotpartners.com

Media: David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-announces-55-million-private-placement-financing-302782701.html

SOURCE Q32 Bio

FAQ

What did Q32 Bio (NASDAQ:QTTB) announce on May 27, 2026 about new financing?

Q32 Bio announced a private placement financing expected to raise approximately $55 million in gross proceeds. According to Q32 Bio, the deal includes common stock and pre-funded warrants sold to new and existing institutional and accredited investors.

How many QTTB shares and pre-funded warrants are in Q32 Bio's May 2026 private placement?

The financing includes 6,725,000 common shares and pre-funded warrants to purchase 150,000 shares. According to Q32 Bio, the pre-funded warrants are immediately exercisable and remain outstanding until they are exercised in full.

What are the pricing terms for Q32 Bio (QTTB) shares and pre-funded warrants in the private placement?

Common shares are priced at $8.00 each, and pre-funded warrants at $7.9999 per warrant. According to Q32 Bio, the warrant price equals the share price minus the $0.0001 per-share exercise price.

Who is leading Q32 Bio (QTTB) $55 million private placement financing?

The private placement is led by BVF Partners, with RA Capital Management, OrbiMed, and Atlas Venture participating. According to Q32 Bio, Morgan Stanley is lead placement agent and Oppenheimer & Co. also acts as a placement agent.

When will Q32 Bio (QTTB) private placement close and how will resale be handled?

The private placement is expected to close on May 28, 2026, subject to customary conditions. According to Q32 Bio, it has agreed to file an SEC registration statement to register resale of the shares and warrant shares.

Are Q32 Bio (QTTB) private placement securities registered under the Securities Act?

The offered securities are not registered under the Securities Act and are sold via private placement. According to Q32 Bio, they may not be publicly sold in the United States without registration or an applicable exemption.